insights_auto
为什么 EVO 下跌了 2.74%?
深入探索chevron_right
EVO:NASDAQ
Evotec SE
US$1.60
arrow_downward
-2.74%(-0.045) 1 天
10月2日, GMT-4 16:00:01 · USD
search
所有股票代码
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 EVO 生成关键数据洞见…
开盘价
US$1.63
最高价
US$1.63
最低价
US$1.59
市值
5.92亿
平均成交量
12.57万
成交量
5.20万
52 周最高价
US$4.27
52 周最低价
US$1.50
每股收益
-US$0.62
Beta 版
1.98
流通股数
3.56亿
员工人数
4461
开盘价
US$1.63
最高价
US$1.63
最低价
US$1.59
市值
5.92亿
平均成交量
12.57万
成交量
5.20万
52 周最高价
US$4.27
52 周最低价
US$1.50
每股收益
-US$0.62
Beta 版
1.98
流通股数
3.56亿
员工人数
4461
新闻报道
来自网络来源和新闻合作伙伴
资料
Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development.
The company's 4,200+ employees work across a number of therapeutic areas including CNS/neurology, metabolic diseases, Cancer, and inflammatory and infectious diseases. It has long-term discovery alliances with Bristol Myers Squibb, Bayer, Sanofi, Boehringer Ingelheim, the CHDI Foundation, Lilly, Takeda, Sernova, and more.
On 28 October 2009 the company was listed on the TecDAX index, which tracks the performance of the 30 largest German companies from the technology sector. On 24 September 2018 Evotec joined the MDAX index, following a rule change that enabled dual listing. The MDAX tracks 60 Prime Standard shares from sectors excluding technology. Wikipedia
Evotec SE简介